company background image
DMKP.Q logo

DMK Pharmaceuticals OTCPK:DMKP.Q Stock Report

Last Price

US$0.07

Market Cap

US$621.3k

7D

27.3%

1Y

-99.1%

Updated

26 Mar, 2024

Data

Company Financials

DMK Pharmaceuticals Corporation

OTCPK:DMKP.Q Stock Report

Market Cap: US$621.3k

DMKP.Q Stock Overview

DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases.

DMKP.Q fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

DMK Pharmaceuticals Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for DMK Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.07
52 Week HighUS$9.45
52 Week LowUS$0.033
Beta0.92
1 Month Change94.44%
3 Month Change-90.78%
1 Year Change-99.13%
3 Year Change-99.89%
5 Year Change-99.95%
Change since IPO-99.99%

Recent News & Updates

Recent updates

Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure

Sep 30

Next meeting of data safety board to review Adamis Pharma's COVID treatment in Sept.

Jul 29

Adamis CEO urges stock split approval, slate of directors in letter to shareholders

Jul 21

Adamis Pharmaceuticals: Preparing For Another Round Of Success, Failure, Then Hope

Apr 13

Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic

Jan 20

Adamis Pharmaceuticals: It's Now Or Never

Dec 02

Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines

Sep 03

Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares

Jun 13

Adamis Pharma gains 9% after Tempol shows potential as an antiviral drug for COVID-19

Jun 07

Adamis pharmaceuticals gets deficiency letter from NASDAQ

May 28

Adamis Pharmaceuticals (ADMP) trades sharply lower after pricing public offering

Jan 29

Adamis Pharma plunges 43% on FDA rejection of Zimhi application for opioid overdose

Nov 16

Adamis Pharmaceuticals EPS misses by $0.01, misses on revenue

Nov 09

Shareholder Returns

DMKP.QUS PharmaceuticalsUS Market
7D27.3%-0.2%0.6%
1Y-99.1%23.9%29.5%

Return vs Industry: DMKP.Q underperformed the US Pharmaceuticals industry which returned 23.1% over the past year.

Return vs Market: DMKP.Q underperformed the US Market which returned 29.8% over the past year.

Price Volatility

Is DMKP.Q's price volatile compared to industry and market?
DMKP.Q volatility
DMKP.Q Average Weekly Movement36.1%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: DMKP.Q's share price has been volatile over the past 3 months.

Volatility Over Time: DMKP.Q's weekly volatility (36%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a12Eddie Gloverhttps://www.dmkpharmaceuticals.com

DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company’s lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose.

DMK Pharmaceuticals Corporation Fundamentals Summary

How do DMK Pharmaceuticals's earnings and revenue compare to its market cap?
DMKP.Q fundamental statistics
Market capUS$621.32k
Earnings (TTM)-US$21.33m
Revenue (TTM)US$3.62m

0.2x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DMKP.Q income statement (TTM)
RevenueUS$3.62m
Cost of RevenueUS$4.97m
Gross Profit-US$1.35m
Other ExpensesUS$19.98m
Earnings-US$21.33m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.11
Gross Margin-37.30%
Net Profit Margin-589.28%
Debt/Equity Ratio0%

How did DMKP.Q perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.